Evidence map›Paper›PMID 25242229›Full record

ArticleMolecular medicine reports2014

A polymorphism site in the pre‑miR‑34a coding region reduces miR‑34a expression and promotes osteosarcoma cell proliferation and migration.

Honglin Lv, Jingfang Pei, Hongtao Liu, Haiyan Wang, Jun Liu

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Effects of microRNAs polymorphism in cancer progression.Medical journal of the Islamic Republic of Iran · 2020
    Review
  5. miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review of microRNA in osteosarcoma and chondrosarcoma.Medical oncology (Northwood, London, England) · 2015
    Review
  15. NFKB1 -94ins/del ATTG polymorphism increases osteosarcoma risk in a Chinese Han population.International journal of clinical and experimental medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Honglin LvDepartment of Spinal Orthopedics, Yantai Yuhuangding Hospital, Medical College of Qingdao University, Yantai, Shandong 264000, P.R. China.
Jingfang PeiDepartment of Spinal Orthopedics, Yantai Yuhuangding Hospital, Medical College of Qingdao University, Yantai, Shandong 264000, P.R. China.
Hongtao LiuDepartment of Spinal Orthopedics, Yantai Yuhuangding Hospital, Medical College of Qingdao University, Yantai, Shandong 264000, P.R. China.
Haiyan WangCentral Laboratory, Yantai Yuhuangding Hospital, Medical College of Qingdao University, Yantai, Shandong 264000, P.R. China.
Jun LiuDepartment of Spinal Orthopedics, Wendeng Orthopedics Hospital, Wendeng, Weihai, Shandong 26440, P.R. China.
Qingdao University · CNYuhuangding Hospital · CNWenzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is the most prevalent primary malignant bone tumor in children and young adults, its complex etiology involving a combination of environmental and genetic factors. MicroRNA (miRNA) is a short, non‑coding regulatory RNA molecule that represses gene expression by imperfectly base‑pairing to the 3' untranslated region of target mRNAs. Evidence has shown that alterations in the expression of miRNA are involved in the initiation, progression, and metastasis of human cancers. It is believed that miRNAs function both as tumor suppressors and oncogenes during cancer development. In the present study, three tumor-associated miRNAs (miR‑21, miR‑34a and miR‑146a) coding regions were screened in Chinese‑Han OS patients. A G>A variation in the pre‑miR‑34a coding region was found to be associated with higher OS morbidity. By detecting the mature miR‑34a expression in cells transfected with pre‑miR‑34a expression vectors of different genotypes using quantitative polymerase chain reaction, it was demonstrated that the G>A variation reduced miR‑34a expression in vitro. This was in accordance with the data collected from tumor tissue and patient serum samples. Subsequently, a dual‑luciferase reporter assay and western blot analysis were used to detect the site variation effect on the expression of c‑Met, a target gene of miR‑34a. The G>A variation downregulated the suppression of c‑Met in two OS cell lines. Furthermore, it was found that reduced miR‑34a expression decreased the suppression of OS cell proliferation in vitro. In conclusion, the present study established the association between miR‑34a and the risk of suffering OS in a Chinese Han population by identifying one functional single nucleotide polymorphism site in pre‑miR‑34a. These findings may give insight into the mechanism of OS development and create an opportunity to approach the diagnosis and treatment of OS.

Indexed as

Bone NeoplasmsCell MovementCell Proliferationc-Mer Tyrosine KinaseDown-RegulationGene Expression Regulation, NeoplasticGenotypeHumansMicroRNAsOpen Reading FramesOsteosarcomaPolymorphism, Single NucleotideProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinasesc-Mer Tyrosine KinaseMERTK protein, humanMicroRNAsMIRN34 microRNA, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Identifiers

PMID25242229
PMCPMC4227432
OpenAlexW2001666533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.